



UNIVERSITEIT VAN PRETORIA  
UNIVERSITY OF PRETORIA  
YUNIBESITHI YA PRETORIA

# **RESPIRATORY HEALTH STATUS IN RELATION TO OCCUPATIONAL EXPOSURE IN URANIUM MINING AND RECOVERY**

BY

**WOTAN REYNIER SIEGFRIED SWIEGERS**

**THESIS SUBMITTED AS PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE PHILOSOPHIAE DOCTOR (Ph.D.) DEGREE IN COMMUNITY HEALTH**

**DEPARTMENT OF COMMUNITY HEALTH  
FACULTY OF MEDICINE  
UNIVERSITY OF PRETORIA  
SOUTH AFRICA**

**SUPERVISOR: PROFESSOR CARL B. IJSSELMUIDEN  
DEPARTMENT OF COMMUNITY HEALTH  
UNIVERSITY OF PRETORIA  
SOUTH AFRICA**

**OCTOBER 1999**

**Dedicated to my friend and mentor,**

**Professor M A (Attie) de Kock**

Our real problem is in the hearts and minds of men.  
It is not a problem of physics, but of ethics.  
Man's skills have outstripped his morals.

His engineering - has leaped ahead of his wisdom.  
We cannot cancel or call back his scientific advances,  
but we can, and must, if the world is to survive,  
help man to catch up.

In God's name, if we still believe in God.  
Take him seriously, and somehow get control,  
of what science has given to the world,  
or else we shall likewise perish.

A. Einstein

## ACKNOWLEDGMENTS

I am deeply grateful to many people who provided time, material and critique that assisted with the realisation of this thesis and would like to thank the following in particular:

**Prof M A de Kock**, an outstanding clinical scientist and human being for support and encouragement through many years and for allowing me to use the opportunities that arose during the course of these projects. He taught me all I know about pulmonary medicine and research, and a great deal about life. None of this would have been possible without him.

**Dr Robert Murray** for broadening my horizons and for teaching me the value of past lessons learned and **Prof Margaret Becklake** for assisting with the initial research protocol. **Prof's Theunis V Z Kotze, D Kotze** and **Dr P Becker** for doing the statistical analysis. **Mr J H I Olivier, Prof J Klopper** and **Dr H J Wassermann**, (Tygerberg Hospital), for determining the uranium in the lung burden. **Dr Johan Deale**, (Tygerberg Hospital), for implementing the Sputum Cytology Programme. **Dr. H W Hitzeroth** of Genetic Services of the Department of National Health and Population Development for doing the (P<sub>1</sub> - typing) Alpha-1-Antitrypsin Study. **Erika Louwrens**, for typing and retyping this thesis.

**Sister Rosa Thalwitzer** and "the team", in particular, **Maira Ruziecki. Rössing Uranium Management** and employees for allowing me to use the occupational health data. I hope this thesis will enable them to explore new avenues for prevention. Last, but not least, **my family** for allowing me to spend so much of "their time" on reading and research. A special word of thanks to my son, **Wotan Swiegers (Jnr)**, who assisted with the compiling of the references.

### DECLARATION

I, the undersigned, declare that the work contained in this thesis (dissertation) is my own original work and it has not been submitted in any form for similar purposes to any University for a degree.

Signed: 

Date: 20 October 1999



## TABLE OF CONTENTS

LIST OF FIGURES.....	10
LIST OF TABLES .....	14
LIST OF GRAPHS .....	19
ABBREVIATIONS AND DEFINITIONS .....	20
SUMMARY.....	25
OPSOMMING .....	27
<b>CHAPTER ONE</b> .....	<b>29</b>
1.1 INTRODUCTION.....	29
1.2 OBJECTIVES .....	33
1.2.1 SPECIFIC OBJECTIVES.....	33
<b>CHAPTER TWO</b> .....	<b>35</b>
2.1 LITERATURE REVIEW (REVIEW OF CURRENT EVIDENCE) .....	35
2.2 HISTORY OF URANIUM MINING .....	35
2.2.1 AGRICOLA (1499 - 1555).....	36
2.2.2 PARACELTUS (1493 - 1541) .....	37
2.2.3 RAMAZZINI (1633 - 1714).....	37
2.2.4 UNRAVELING SCHNEEBERG BERGKRANKHEID .....	38
2.3 URANIUM .....	41
2.3.1 URANIUM MINING .....	41
2.3.2 URANIUM - THE METAL .....	41
2.3.3 CHEMISTRY .....	42
2.3.4 DISTRIBUTION OF URANIUM .....	42
2.3.5 RADIOACTIVITY .....	43
2.3.6 RADON .....	44
2.3.7 HEALTH EFFECTS ASSOCIATED WITH THE MINING AND MILLING OF URANIUM .....	44
2.3.7.1 Toxic Effects .....	44
2.3.7.2 Radiation Effects.....	46
2.3.7.3 External Radiation .....	46
2.3.7.4 Internal Radiation.....	50
2.4 ENVIRONMENT AND THE RESPIRATORY TRACT.....	53
2.4.1 INTRODUCTION .....	53
2.4.2 AIR POLLUTION .....	55
2.4.3 PARTICLE MECHANICS .....	56
2.4.4 DEFENSE MECHANISMS .....	57
2.4.4.1 Physical.....	57
2.4.4.2 Cellular (Cell Mediated) Immunity .....	58
2.4.5 IMMUNOLOGICAL REACTIONS.....	59
2.4.6 IMMUNOPATHOLOGY .....	60
2.4.7 ALLERGIC DISEASES.....	61
2.4.8 GENETIC PREDISPOSITION .....	63
2.4.9 ALLERGEN EXPOSURE .....	64
2.4.10 CONTRIBUTING FACTORS .....	65
2.4.11 EOSINOPHILS .....	66
2.4.12 OXYGEN-RADICALS, LUNG INJURY AND REPAIR.....	67
2.4.13 ALPHA-1 ANTITRYPSIN.....	68
2.4.14 THE ROLE OF SMOKING AND ENVIRONMENTAL POLLUTION.....	69
2.4.15 THE NET EFFECT .....	70
2.5 ACUTE IRRITATION AND INFLAMMATORY LUNG DISEASE .....	71



<b>2.6</b>	<b>CHRONIC INFLAMMATORY LUNG DISEASES</b> .....	<b>73</b>
2.6.1	ASTHMA .....	74
2.6.1.1	Clinical.....	74
2.6.1.2	Epidemiology .....	76
2.6.2	CHRONIC OBSTRUCTIVE PULMONARY DISEASE .....	79
2.6.2.1	Small Airways Disease.....	79
2.6.2.2	Chronic Bronchitis.....	80
2.6.2.3	Emphysema .....	81
2.6.2.4	Epidemiology .....	81
<b>2.7</b>	<b>LUNG DISEASES ASSOCIATED WITH PROGRESSIVE FIBROSIS</b> .....	<b>85</b>
2.7.1	INTRODUCTION .....	85
2.7.2	SILICOSIS .....	86
2.7.2.1	Determinants of Fibrogenesis.....	86
2.7.2.2	Individual Predisposition to Silicosis .....	87
2.7.2.3	Pathology .....	87
2.7.2.4	Silicosis and Symptoms .....	88
2.7.2.5	Silicosis and COPD .....	89
2.7.2.6	Lung Function in Silicosis.....	89
2.7.2.7	Silica Exposure and Tuberculosis .....	90
2.7.2.8	Silica as a Carcinogen .....	91
2.7.3	ASBESTOS RELATED DISEASES .....	92
2.7.3.1	Asbestos Exposure .....	92
2.7.3.2	Asbestosis .....	93
2.7.3.3	Pleural Asbestosis .....	93
2.7.3.4	Bronchogenic Carcinoma.....	94
2.7.3.5	Mesothelioma of the Pleura .....	94
<b>2.8</b>	<b>LUNG DISEASES ASSOCIATED WITH CARCINOGENESIS</b> .....	<b>95</b>
2.8.1	INTRODUCTION .....	95
2.8.2	HISTOLOGY .....	96
2.8.3	LUNG CANCER .....	97
2.8.3.1	Causes of Lung Cancer .....	98
2.8.3.2	Histology .....	99
2.8.3.3	Epidemiology.....	100
2.8.3.4	Other Environmental Causes .....	105
<b>CHAPTER THREE</b> .....		<b>106</b>
<b>3.1</b>	<b>PULMONARY FUNCTION TESTS</b> .....	<b>106</b>
3.1.1	INTRODUCTION .....	106
3.1.2	STANDARDISATION .....	107
3.1.3	SPIROMETRY .....	108
3.1.4	THE MAXIMAL EXPIRATORY FLOW VOLUME CURVE (MEFVC) .....	110
3.1.4.1	Time Factors in Relation to the MEFV Curve.....	110
3.1.4.2	Shape of the MEFV Curve .....	111
3.1.4.3	Peak Expiratory Flow Rate (PEFR) .....	114
3.1.4.4	Flow Rates at Lower Lung Volumes (Forced Expiratory Flow {FEF} at Specified Volumes) .....	115
3.1.4.5	Evaluation of the Maximal Inspiratory Flow Volume (MIFV) Curve .....	116
3.1.4.6	Tests for Detecting the Extent of Small Airways Impairment .....	118
3.1.4.7	Prediction of "Normal" Values for Lung Function Measurements.....	120
3.1.4.8	Interpretation of Pulmonary Function Tests .....	124
3.1.4.9	Clinical guidelines .....	126
3.1.4.10	Pulmonary Function Tests in an Epidemiological Study .....	127
<b>CHAPTER FOUR</b> .....		<b>128</b>
<b>4.1</b>	<b>METHODOLOGY</b> .....	<b>128</b>
4.1.1	FORMULATION OF PROBLEMS AND HYPOTHESES .....	128
4.1.2	STUDY PLAN AND TIME FRAME .....	129
4.1.2.1	Introduction.....	129

4.1.2.2	Project Organisation.....	130
4.1.2.3	Time Frame.....	130
4.1.3	STUDY DESIGN.....	132
4.1.3.1	Cross-Sectional Studies.....	132
4.1.3.2	Case Control Study.....	132
4.1.3.3	Criteria for Admissibility.....	133
4.1.3.4	Population and Sample Size.....	134
4.1.4	ASSESSMENT OF HEALTH EFFECTS.....	136
4.1.5	RESPIRATORY FUNCTION MEASUREMENTS.....	136
4.1.5.1	General Comments regarding Equipment and Quality Control.....	136
4.1.5.2	Procedure for the Flow Volume Curve.....	138
4.1.6	CROSS-SECTIONAL STUDY.....	141
4.1.7	ANALYTICAL CROSS-SECTIONAL AND CASE CONTROL STUDY.....	142
4.1.8	RADIOLOGICAL EXAMINATION OF THE CHEST (CHEST X-RAYS).....	144
4.1.9	SPUTUM CYTOLOGY.....	145
4.1.10	ALPHA-1-ANTITRYPSIN.....	145
4.1.11	DETERMINATION OF URANIUM IN THE LUNG.....	146
4.1.12	CLINICAL MANAGEMENT.....	146
4.1.13	ASSESSMENT OF EXPOSURE.....	147
4.1.14	ENVIRONMENTAL CHARACTERISATION.....	148
4.1.15	METEOROLOGICAL MONITORING.....	148
4.1.16	RADIATION MONITORING.....	150
4.1.17	DUST MONITORING.....	154
4.1.18	GASES/FUMES AND ACID/ALKALINE MIST.....	156
4.1.19	ASBESTOSIS MONITORING.....	157
4.1.20	FINAL PRODUCT STACK MEASUREMENTS.....	158
4.1.21	ENVIRONMENTAL EXPOSURE GRADING.....	158
4.1.22	COLLECTION PROCEDURES.....	160
4.1.23	DATA ANALYSIS.....	160
4.1.24	ETHICAL ISSUES.....	162
	<b>CHAPTER FIVE.....</b>	<b>163</b>
<b>5.</b>	<b>RESULTS.....</b>	<b>163</b>
<b>5.1</b>	<b>PHASE I – LUNG FUNCTION STUDIES.....</b>	<b>163</b>
5.1.1	EXPLORATORY LUNG FUNCTION STUDY.....	163
5.1.1.1	Objective.....	163
5.1.1.2	Introduction.....	163
5.1.1.3	Method.....	164
5.1.1.4	Analyses.....	165
5.1.1.5	Application.....	167
5.1.1.6	Recommendations.....	168
5.1.2	EXPLORATORY CROSS-SECTIONAL LUNG HEALTH STUDY.....	169
5.1.2.1	Objective.....	169
5.1.2.2	Introduction.....	170
5.1.2.3	Study Population.....	170
5.1.2.4	Methods for demonstrating early small airway involvement.....	171
<b>5.2</b>	<b>PHASE II – PILOT STUDIES.....</b>	<b>179</b>
5.2.1	ALPHA-1-ANTITRYPSIN STUDY.....	179
5.2.1.1	Objective.....	179
5.2.1.2	Introduction.....	179
5.2.1.3	Genetics.....	180
5.2.1.4	The Role of Smoking and Environmental Pollution.....	181
5.2.1.5	Clinical Aspects.....	181
5.2.1.6	Method.....	182
5.2.1.7	Results.....	183
5.2.1.8	Conclusion.....	183
5.2.2	URANIUM LUNG BURDEN STUDY – IN VIVO MEASUREMENT OF URANIUM IN THE HUMAN CHEST.....	183



5.2.2.1	Objective .....	183
5.2.2.2	Introduction .....	183
5.2.2.3	Environmental Monitoring.....	184
5.2.2.4	Annual Limit Intake.....	185
5.2.2.5	In Vivo Lung Burden Measurements .....	185
5.2.2.6	Method .....	187
5.2.2.7	Measuring Rössing Uranium Mine Personnel .....	188
5.2.2.8	Results and Discussion.....	188
5.2.2.9	Prediction of Uncontaminated Count Rates .....	189
5.2.2.10	Rössing Personnel .....	190
5.2.2.11	Conclusion.....	191
5.2.3	SPUTUM CYTOLOGY.....	191
5.2.3.1	Objective .....	191
5.2.3.2	Discussion.....	191
5.2.3.3	Sputum Cytology Programme .....	193
5.2.3.4	Conclusion .....	194
<b>5.3</b>	<b>PHASE III – MAIN STUDIES .....</b>	<b>196</b>
5.3.1	CROSS-SECTIONAL STUDY OF URANIUM MINE WORKERS TO DEVELOP PREDICTIVE EQUATIONS FOR LUNG FUNCTIONS WITH REFERENCE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE .....	196
5.3.1.1	Study population .....	196
5.3.1.2	Smoking Profile.....	197
5.3.1.3	Analysis of lung function values .....	197
5.3.1.4	Evaluation of the Schoenberg standardisation formulae for lung function test in non-smokers.....	198
5.3.1.5	Prediction of unstandardised or 'raw' lung function measurements.....	211
5.3.1.6	Prediction of FVC of non-smokers .....	212
5.3.1.7	Prediction of the FEV <sub>1</sub> of non-smokers .....	213
5.3.1.8	Prediction of FEF <sub>50</sub> of non-smokers .....	214
5.3.1.9	Prediction of FEF <sub>75</sub> in non-smokers .....	215
5.3.1.9	Prediction of PEFR in non-smokers .....	216
5.3.1.10	Prediction of PIFR in non-smokers.....	217
5.3.1.11	Conclusion.....	218
5.3.1.12	Comparison of the prediction formulae described in this paper with the formulae of Schoenberg et al. ....	220
5.3.1.13	Abnormal lung function measurements indicating early airway impairment .....	223
5.3.2	RESULTS OF THE ANALYTICAL CROSS-SECTIONAL STUDY OF X-RAYS AND LUNG FUNCTIONS TO STUDY SIGNIFICANT DIFFERENCES FROM PREDICTED MEASUREMENTS AMONG A WORKFORCE WITH MORE THAN 10 YEARS EXPOSURE IN URANIUM MINING AND MILLING.....	225
5.3.2.1	Study population .....	226
5.3.2.2	Exposure Groups .....	227
5.3.2.3	Smoking profile .....	228
5.3.2.4	Allergic Profile .....	229
5.3.2.5	Analysis of demographic data .....	230
5.3.3	ANALYSIS OF CHEST X-RAY DATA.....	236
5.3.3.1	Normal.....	238
5.3.3.2	Pneumoconiosis.....	238
5.3.3.3	Lung cancer .....	238
5.3.3.4	Tuberculosis confirmed or strongly suspected .....	238
5.3.4	ANALYSIS OF LUNG FUNCTION VALUES.....	239
<b>5.4</b>	<b>PHASE IV – CASE CONTROL STUDY OF THE RESPIRATORY HEALTH OF URANIUM WORKERS (AFTER 23 YEARS OF EXPOSURE TO URANIUM/SILICA DUST) .....</b>	<b>264</b>
5.4.1	INTRODUCTION .....	264
5.4.2	STUDY POPULATION .....	264
5.4.3	SMOKING STATUS.....	266
5.4.4	ALLERGY STATUS .....	268





5.4.5	RESULTS OF CHEST RADIOGRAPHS.....	270
5.4.6	RESULTS OF LUNG FUNCTION ANALYSIS .....	271
5.4.7	THE COMPARISON OF SMOKING CATEGORIES WITH LUNG FUNCTION VARIABLES.....	274
5.4.7	THE RELATIONSHIP BETWEEN EXPOSURE AND OUTCOME VARIABLES .....	285
	<b>CHAPTER SIX .....</b>	<b>288</b>
	<b>DISCUSSION .....</b>	<b>288</b>
6.1	<b>GENERAL COMMENTS .....</b>	<b>288</b>
6.2	<b>EXPOSURE .....</b>	<b>290</b>
6.3	<b>CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), ASTHMA AND CHRONIC NON SPECIFIC LUNG DISEASE (CNSLD).....</b>	<b>293</b>
6.4	<b>SILICOSIS AND ASBESTOSIS .....</b>	<b>295</b>
6.5	<b>LUNG CANCER.....</b>	<b>297</b>
6.6	<b>TUBERCULOSIS .....</b>	<b>300</b>
6.7	<b>SARCOIDOSIS .....</b>	<b>303</b>
6.8	<b>LUNG FUNCTION EVALUATION OF URANIUM WORKERS.....</b>	<b>304</b>
6.9	<b>CONCLUSION .....</b>	<b>310</b>
	<b>REFERENCES - SELECTED BIBLIOGRAPHY .....</b>	<b>314</b>
	<b>APPENDIX A.....</b>	<b>341</b>
	<b>APPENDIX B.....</b>	<b>342</b>

## LIST OF FIGURES

---

Figure	Title	Page
1	Relationship between the spirogram and the MEFV Curve.....	112
2	Standard Rössing lung function test.....	113
3	Box diagram of the observations of FVC separated according to ethnic group and smoking habit .....	201
4	Box diagram of the observations of FEV <sub>1</sub> separated according to ethnic group and smoking habit .....	201
5	Box diagram of the observations of PEFR separated according to ethnic group and smoking habit .....	201
6	Box diagram of the observations of PIFR separated according to ethnic group and smoking habit .....	201
7	Box diagram of the observations of FEF <sub>25</sub> separated according to ethnic group and smoking habit .....	201
8	Box diagram of the observations of FEF <sub>50</sub> separated according to ethnic group and smoking habit .....	201
9	Box diagram of the observations of FEF <sub>75</sub> separated according to ethnic group and smoking habit .....	202
10	Box diagram of the observations of FEV <sub>1</sub> /FVC ratios separated according to ethnic group and smoking habit.....	202
11	Box diagram of age for non-smoking males divided into three ethnic groups .....	202
12	Box diagram of height for non-smoking males divided into three ethnic groups .....	202
13	Box diagram of mass for non-smoking males divided into three ethnic groups .....	202
14	Box diagram of the observations of standardised FVC according to Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	202
15	Box diagram of the observations of standardised FEV <sub>1</sub> according to Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	203

16	Box diagram of the observations of standardised PEFR according to Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	203
17	Box diagram of the observations of standardised PIFR according to Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	203
18	Box diagram of the observations of standardised FEF <sub>25</sub> according to Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	203
19	Box diagram of the observations of standardised FEF <sub>50</sub> according to Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	203
20	Box diagram of the observations of standardised FEF <sub>75</sub> according to Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	203
21	Box diagram comparing the FVC between comparable groups of Caucasians and blacks .....	204
22	Box diagram comparing the FEV <sub>1</sub> between comparable groups of Caucasians and blacks .....	204
23	Box diagram comparing the FEF <sub>25</sub> between comparable groups of Caucasians and blacks .....	204
24	Box diagram comparing the FEF <sub>50</sub> between comparable groups of Caucasians and blacks .....	204
25	Box diagram comparing the FEF <sub>75</sub> between comparable groups of Caucasians and blacks .....	204
26	Box diagram comparing the PEFR between comparable groups of Caucasians and blacks .....	204
27	Box diagram comparing the PIFR between comparable groups of Caucasians and blacks .....	205
28	Box diagram of the difference in the percentage of predicted of the FVC according to the formula described and the formula of Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	205
29	Box diagram of the difference in the percentage of predicted	

	of the FEV <sub>1</sub> according to the formula described and the formula of Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	205
30	Box diagram of the difference in the percentage of predicted of the PEFr according to the formula described and the formula of Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	205
31	Box diagram of the difference in the percentage of predicted of the PIFR according to the formula described and the formula of Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	205
32	Box diagram of the difference in the percentage of predicted of the FEF <sub>50</sub> according to the formula described and the formula of Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	205
33	Box diagram of the difference in the percentage of predicted of the FEF <sub>75</sub> according to the formula described and the formula of Schoenberg <i>et al</i> , separated according to ethnic group and smoking habit.....	206
34	Box diagram of the observations of FEF <sub>25</sub> /PEFR ratio separated according to ethnic group and smoking habit.....	206
35	Box diagram of the observations of FEF <sub>50</sub> /PEFR ratio separated according to ethnic group and smoking habit.....	206
36	Box diagram of the observations of FEF <sub>75</sub> /PEFR ratio separated according to ethnic group and smoking habit.....	206
37	Box plots of age for exposure groups.....	232
38	Box plots of height for exposure groups.....	233
39	Box plots of weight for exposure groups .....	234
40	Box plots of FVC for exposure groups .....	243
41	Box plots of FVC adjusted for exposure groups.....	244
42	Box plots of FVC percentage for exposure groups .....	245
43	Box plots of FEV <sub>1</sub> for exposure groups .....	246
44	Box plots of FEV <sub>1</sub> adjusted for exposure groups.....	247
45	Box plots of FEV <sub>1</sub> percentage for exposure groups .....	248

46	Box plots of FEV <sub>1</sub> /FVC for exposure groups .....	249
47	Box plots of FEV <sub>1</sub> /FVC adjusted for exposure groups.....	250
48	Box plots of FEV <sub>1</sub> /FVC percentage for exposure groups .....	251
49	Box plots of FEF <sub>50</sub> for exposure groups .....	252
50	Box plots of FEF <sub>50</sub> adjusted for exposure groups.....	253
51	Box plots of FEF <sub>50</sub> percentage for exposure groups .....	254
52	Box plots of FEF <sub>75</sub> for exposure groups .....	255
53	Box plots of FEF <sub>75</sub> adjusted for exposure groups.....	256
54	Box plots of FEF <sub>75</sub> percentage for exposure groups .....	257
55	Box plots of PEFR for exposure groups .....	258
56	Box plots of PEFR adjusted for exposure groups .....	259
57	Box plots of PEFR percentage for exposure groups .....	260
58	Box plots of FIVC for exposure groups .....	261
59	Box plots Schoenberg FVC predicted .....	275
60	Box plots Schoenberg FEV <sub>1</sub> predicted .....	276
61	Box plots Schoenberg ratio predicted .....	277
62	Box plots Schoenberg FEF <sub>50</sub> predicted.....	278
63	Box plots Schoenberg FEF <sub>75</sub> predicted.....	279
64	Box plots de Kock FVC predicted .....	280
65	Box plots de Kock FEV <sub>1</sub> predicted .....	281
66	Box plots de Kock ratio predicted.....	282
67	Box plots de Kock FEF <sub>50</sub> predicted .....	283
68	Box plots de Kock FEF <sub>75</sub> predicted.....	284

## LIST OF TABLES

---

Table Title	Page
1 Association between exposure and lung cell type .....	100
2 Summary of principal studies of lung cancer mortality in underground mine workers exposed to radon progeny.....	102
3 Summary of additional studies of lung cancer mortality in underground mine workers exposed to radon progeny.....	103
4 Relative risk estimates of lung cancer at age 60 by annual and lifetime cumulative exposures to radon progeny .....	104
5 Timeframe of respiratory health study together with reporting dates ...	131
6 Pulmonary function variables.....	144
7 Abnormal lung function management protocol .....	146
8 Background radiation.....	150
9 Radiation exposure in working levels in residential areas.....	152
10 Radiation exposure in working levels in operational areas .....	152
11 Annual radiation internal dose of a worker and estimated risk.....	153
12 Annual radiation external dose of a worker and estimated risk.....	153
13 Average annual respirable dust levels in mg/m <sup>3</sup> .....	155
14 Asbestos type and threshold limit vale.....	158
15 Bouhuys minima .....	166
16 Bouhuys norms.....	166
17 Abnormalities according to method used.....	167
18 Comparing different criteria for abnormal lung functions .....	168
19 Manpower and number of starters and leavers .....	170
20 Ethnic distribution of population.....	171
21 Ethnic distribution of smokers .....	171
22 Reference values used by Tygerberg Hospital – 1983 .....	174
23 Percentage abnormal lung functions .....	175
24 Ethnic distribution of study population .....	175
25 Mean values of lung function parameters in various ethnic groups .....	176

26	Distribution of abnormal lung functions according to work areas for Caucasians.....	177
27	Distribution of abnormal lung functions according to work areas for black people.....	177
28	Distribution of abnormal lung functions according to work areas for mixed races.....	178
29	Sputum sample results .....	193
30	Smoking habit frequency and percentage smokers in the three ethnic groups.....	197
31	Results from a stepwise regression to predict standardised FVC of non-smokers in the 3 ethnic groups by means of height, mass and age ....	207
32	Results from a stepwise regression to predict standardised FEV <sub>1</sub> of non-smokers in the 3 ethnic groups by means of height mass and age .....	208
33	Results from a stepwise regression to predict standardised FEF <sub>50</sub> of non-smokers in the 3 ethnic groups by means of height, mass and age ....	209
34	Results from a stepwise regression to predict standardised FEF <sub>75</sub> of non-smokers in the 3 ethnic groups by means of height, mass and age ....	209
35	Results from a stepwise regression to predict standardised PEFR of non-smokers in the 3 ethnic groups by means of height, mass and age ....	210
36	Results from a stepwise regression to predict standardised PIFR of non-smokers in the 3 ethnic groups by means of height, mass and age ....	210
37	Coefficients from a stepwise regression to predict the FVC of non-smokers in the 3 ethnic groups by means of height, mass and age.....	213
38	Coefficients from a stepwise regression to predict the FEV <sub>1</sub> of non-smokers in the 3 ethnic groups by means of height, mass and age ....	214
39	Coefficients from a stepwise regression to predict the FEF <sub>50</sub> of non-smokers in the 3 ethnic groups by means of height, mass and age ....	215
40	Coefficients from a stepwise regression to predict the FEF <sub>75</sub> of non-smokers in the 3 ethnic groups by means of height, mass and age ....	216
41	Coefficients from a stepwise regression to predict the PEFR of non-smokers in the 3 ethnic groups by means of height, mass and age ....	217
42	Coefficients from a stepwise regression to predict the PIFR of non-smokers in the 3 ethnic groups by means of height, mass and age ....	218
43	Comparison of predicted formulae with that of Schoenberg <i>et al.</i> .....	223



44	Percentage abnormal values in three ethnic groups according to the formulae of Schoenberg <i>et al</i> .....	225
45	Control group – smoking by ethnic group .....	229
46	Study group – smoking by ethnic group.....	229
47	Terminated group – smoking by ethnic group.....	229
48	Allergy by ethnic group in control, study and terminated groups .....	230
49	Summary of demographic data per exposure group, high & medium ..	230
50	Summary of demographic data per exposure group, low .....	231
51	Summary of demographic data terminated group, exposure medium ..	231
52	Descriptive statistics of age for exposure groups.....	232
53	Descriptive statistics of height for exposure groups.....	233
54	Descriptive statistics of weight for exposure groups .....	234
55	Summary of chest x-ray results of control, study & terminated groups	237
56	Summary of mean lung function parameters of various exposure groups.....	240
57	Summary of mean lung function parameters percentage predicted in various exposure groups .....	241
58	Descriptive statistics of FVC for exposure groups .....	243
59	Descriptive statistics of FVC adjusted for exposure groups.....	244
60	Descriptive statistics of FVC percentage for exposure groups .....	245
61	Descriptive statistics of FEV <sub>1</sub> for exposure groups .....	246
62	Descriptive statistics of FEV <sub>1</sub> adjusted for exposure groups.....	247
63	Descriptive statistics of FEV <sub>1</sub> percentage for exposure groups .....	248
64	Descriptive statistics of FEV <sub>1</sub> /FVC for exposure groups .....	249
65	Descriptive statistics of FEV <sub>1</sub> /FVC adjusted for exposure groups.....	250
66	Descriptive statistics of FEV <sub>1</sub> /FVC percentage for exposure groups ...	251
67	Descriptive statistics of FEF <sub>50</sub> for exposure groups .....	252
68	Descriptive statistics of FEF <sub>50</sub> adjusted for exposure groups.....	253
69	Descriptive statistics of FEF <sub>50</sub> percentage for exposure groups .....	254
70	Descriptive statistics of FEF <sub>75</sub> for exposure groups .....	255
71	Descriptive statistics of FEF <sub>75</sub> adjusted for exposure groups.....	256
72	Descriptive statistics of FEF <sub>75</sub> percentage for exposure groups .....	257
73	Descriptive statistics of PEF <sub>R</sub> for exposure groups .....	258
74	Descriptive statistics of PEF <sub>R</sub> adjusted for exposure groups .....	259



75	Descriptive statistics of PEFR percentage for exposure groups .....	260
76	Descriptive statistics of FIVC for exposure groups .....	261
77	Characteristics of the study population .....	266
78	Smoking status of total population .....	266
79	Smoking status by race .....	267
80	Smoking status by exposure.....	267
81	Summary of pack years .....	267
82	Peripheral leucocyte count per smoking category .....	267
83	Smoking category by age .....	268
84	Smoking category by height .....	268
85	Smoking category by weight.....	268
86	Allergy status of the study population .....	269
87	Allergy status by age .....	269
88	Asthma by allergy .....	269
89	Asthma by age.....	269
90	Allergy by smoking.....	270
91	Asthma by smoking .....	270
92	Results of x-ray analysis.....	271
93	Results of chest x-ray analysis according to smoking category.....	271
94	Percentage abnormal lung functions of total population using Schoenberg <i>et al</i> and de Kock <i>et al</i> prediction formulae.....	272
95	Abnormal lung function values in various smoking categories.....	273
96	COPD and SAD in various smoking categories of the total population .....	274
97	Summary of Schoenberg FVC predicted .....	275
98	Summary of Schoenberg FEV <sub>1</sub> predicted .....	276
99	Summary of Schoenberg ratio predicted .....	277
100	Summary of Schoenberg FEF <sub>50</sub> predicted.....	278
101	Summary of Schoenberg FEF <sub>75</sub> predicted.....	279
102	Summary of de Kock FVC predicted.....	280
103	Summary of de Kock FEV <sub>1</sub> predicted .....	281
104	Summary of de Kock ratio predicted.....	282
105	Summary of de Kock FEF <sub>50</sub> predicted .....	283
106	Summary of de Kock FEF <sub>75</sub> predicted .....	284



107	Relationship between exposure groups and outcome variables for the total population according to predictive equations of Schoenberg <i>et al</i> and de Kock <i>et al</i> .....	286
108	Relationship between exposure groups and outcome variables for non-smokers and the predicted equations of Schoenberg <i>et al</i> and de Kock <i>et al</i> .....	287



## LIST OF GRAPHS

---

Graph	Title	Page
1	Rössing manpower levels .....	135
2	Rössing leavers and starters .....	135
3	Rainfall at Rössing .....	148
4	Age distribution .....	264
5	Service distribution .....	265
6	Fatalities at Rössing .....	290
7	Total injuries at Rössing .....	290
8	Open pit dust control .....	291
9	Radiation exposure levels .....	292
10	Tuberculosis detection rates .....	300
11	Number of HIV tests done in the Erongo region .....	302
12	Total injuries .....	349
13	On and off the job injuries .....	350
14	Off the job injuries .....	350



**ABBREVIATIONS AND DEFINITIONS**

<u>AEC:</u>	Atomic Energy Corporation (R.S.A.)
<u>Alpha decay:</u>	Radioactive disintegration resulting in emission of $\alpha$ -particle. Also alpha disintegration.
<u>Alpha Particle:</u>	Nucleus of helium atom of mass number four, consisting of two neutrons and two protons and so double positively charged. Emitted from natural or radioactive isotopes. Often written $\alpha$ -particle
<u>ATC:</u>	American Thoracic Society
<u>Atomic number (Z):</u>	Number of protons
<u>BEIR IV</u>	U.S. Academy of Science Committee on Biological Effects of Ionizing Radiation.
<u>Best practical means</u>	Term with statutory force since 1863, and the basis for control of atmospheric pollution in the UK. Defined as the best practicable means with regard to local conditions, financial implications and current technical knowledge, and includes the provision, maintenance and correct use of plant. Abbreviated BPM.
<u>Beta decay:</u>	Radioactive disintegration with the emission of an electron or positron accompanied by an uncharged antineutrino or neutrino. The mass number of the nucleus remains unchanged but the atomic number is increased by one or decreased by one depending on whether an electron or positron is emitted.
<u>Beta particle:</u>	An electron or positron emitted in beta decay from a radioactive isotope.
<u>Bq:</u>	Symbol for becquerel, the SI unit of radioactivity.
<u>CNSLD</u>	Chronic Non Specific Lung Disease
<u>COPD</u>	Chronic Obstructive Pulmonary Disease
<u>Daughter Product</u>	A nuclide that originates from the radioactive disintegration of a parent nuclide. Also decay product.
<u>Decay:</u>	The process of spontaneous transformation of a radionuclide. Radioactive Decay: Disintegration of the nucleus of an unstable nuclide by spontaneous emission of charged particle, photons, or both.
<u>Dose equivalent:</u>	The quantity obtained by multiplying the absorbed dose by a factor to allow for the different effectiveness of the various ionizing radiations in causing harm to tissues.
<u>Dose:</u>	General term for quantity of radiation.
<u>ECCS</u>	European Community for Coal and Steel
<u>Element :</u>	Material whose atoms all have the same number of protons.
<u>EPA:</u>	Environmental Protection Agency
<u>ERS:</u>	European Respiratory Society



<u>Worker's Daily Exposure:</u>	The average work shift concentration of radon progeny for each work area shall be used to calculate each miner's daily exposure. If no monitoring has been conducted in a work area on a particular day, the daily average work shift concentration for that area shall be determined by averaging the results obtained on the last day of the monitoring with the results from the next day that monitoring is conducted.
<u>FEF<sub>25</sub></u>	The forced expiratory flow after a quarter (25%) of the FVC has been exhaled.
<u>FEF<sub>50</sub></u>	The forced expiratory flow after half (50%) of the FVC has been exhaled.
<u>FEF<sub>75</sub></u>	The forced expiratory flow after three-quarters (75%) of the FVC has been exhaled.
<u>FEV<sub>1</sub></u>	The FEV <sub>1</sub> is the volume of air forcefully expired over the first 1 second of the FVC maneuver.
<u>FEV<sub>1</sub>%</u>	The FEV <sub>1</sub> % is the ratio of the FEV <sub>1</sub> and FVC expressed as a percent (i.e. FEV <sub>1</sub> /FVC x 100)
<u>FEV<sub>1</sub>/FEVC%</u>	The forced expiratory volume (over 1 second) divided by the forced inspiratory vital capacity expressed as a percentage.
<u>FIVC</u>	FIVC is the volume of gas that can be forcefully inspired from RV to TLC.
<u>Follow-up Period</u>	The length of time between a person entering an epidemiological study cohort and the present report (or the end of the study).
<u>FRC</u>	Functional residual capacity - the amount of air that remains in the lungs after a normal resting expiration.
<u>FVC</u>	The FVC is the volume of air that can be expired as forcefully and rapidly as possible from TLC to RV.
<u>FVC/FIVC</u>	The forced vital capacity (FVC) divided by the forced inspiratory vital capacity (FIVC) expressed as a ratio.
<u>Gamma Radiation</u>	Electromagnetic radiation of high quantum energy emitted after nuclear reactions or by radioactive atoms when the nucleus is left in an excited state after emission of alpha or beta particles. Also gamma rays.
<u>Half-Life:</u>	The time required for a radioactive substance to decay to one half of its initial activity.
<u>ICRP:</u>	International Commission on Radiological Protection.
<u>Ion:</u>	Strictly, any atom or molecule that has resultant electric charge due to loss or gain of valency electrons. Free electrons are sometimes loosely classified as negative ions.
<u>Ionisation:</u>	Formation of ions by separating atoms, molecules or radicals, or by adding or subtracting electrons from atoms by strong electric fields in gas, or by weakening the electric attractions in a liquid, particularly water.

<u>Ionising energy:</u>	The energy required to produce an ion pair in a gas under specified conditions. Measured in eV. Air is about 32 eV.
<u>Ionising radiation</u>	Any electromagnetic or particulate radiation capable of producing ions, directly or indirectly, in its passage through matter
<u>Isotope :</u>	One of several nuclides with the same atomic number i.e. one of a set of chemically identical species of atoms which have the same atomic number but different mass numbers. A few elements have only one natural isotope.
<u>Linear Hypothesis:</u>	The hypothesis that excess risk is proportional to dose.
<u>Mass number (A)</u>	Number of protons plus neutrons.
<u>MRC:</u>	Medical Research Council.
<u>MVV</u>	The maximum volume that can be breathed per minute by voluntary effort.
<u>NRPB</u>	National Radiological Protection Board (U.K.)
<u>Nuclear energy:</u>	In principle, the binding energy of a system of particles forming an atomic nucleus. More usually, the energy released during nuclear reactions involving regrouping of such particles (e.g. fission or fusion processes). The term atomic energy is deprecated as it implies rearrangement of atoms rather than of nuclear particles.
<u>Nuclide :</u>	An atomic nucleus as characterized by its atomic number, its mass number and nuclear energy state.
<u>PEFR</u>	The maximum flow rate attained during an FVC maneuver recorded in litres per second.
<u>Person Years (PY):</u>	A standard technique for handling variable follow-up periods; multiply the number of persons by the number of years of follow-up. Person-years at Risk (PYR): In a life table analysis, the number of PY at risk of dying from disease, usually calculated from the time the miner enters the cohort until death or the end of follow-up. Some authors adjust the PYR for an assumed 10-year latent period for lung cancer by subtracting PYR accumulated during the first 10 years after a miner starts to work underground [see above, (Lagging)].
<u>PIFR</u>	The maximum inspiratory flow rate attained during an FIVC maneuver recorded in liters per second.
<u>Radiation:</u>	The dissemination of energy from a source. The energy falls off as the inverse square of the distance from the source in the absence of absorption. The term is applied to electromagnetic waves (radio waves, infrared, light, x-rays, $\gamma$ -rays etc) and to acoustic waves. It is also applied to emitted particle ( $\alpha$ , $\beta$ , protons, neutrons etc)
<u>Radon (Rn) or Radon and its progeny</u>	Specifically refers to the "parent" noble gas (Rn-222), and its short-lived alpha radiation emitting radioactive decay products ("progeny" or "daughters"). Radon is a gas, the radon progeny are radioactive solids.





<u>Rössing Worker</u>	Rössing workers include all mine personnel who are employed by Rössing Uranium (eg drilling, blasting, haulage, maintenance, laboratories, administrative personnel etc)
<u>RV</u>	Residual volume - the amount of air that is left in the lung after a maximal inspiration.
<u>Sievert (Sv):</u>	The SI unit for dose equivalent, measured in grays times a quality factor for the type of radiation and a weighting factor for the tissue irradiated. Numerically equivalent to gray for electrons and X-rays irradiating the whole body. Symbol Sv. Sievert = grays of QF x modifying factors. The QF for alpha particles from inhaled radon progeny is generally considered to be in the range of 10 to 20.
<u>Thoron</u>	A metallic radioactive element, dark-gray in colour. Symbol Th, At. No. 90, r.a.m. 232.0381, mp 1845°C, rel.d. 11.2. Its abundance in the Earth's crust is 8.1ppm and there are few independent thorium minerals. It has six isotopes: Thoron progeny are the solid, short-lived, alpha radiation emitting decay products (progeny or daughters) of thoron gas.
<u>TLC</u>	Total lung capacity is the maximum amount of air that can be held in the lung after deep inspiration.
<u>UNSCEAR</u>	United Nations Scientific Committee of the effects of Atomic Radiation (U.S.)
<u>Uranium</u>	A hard grey metal. Symbol U, at no 92, r.a.m. 238.03, mp 1150°C, rel.d. 18.68. It has seven isotopes. Because the half life of uranium -235 is very much less than that of uranium -238 the relative abundance of these two isotopes has varied over time with uranium -235 being about 3% 2 x 10 <sup>9</sup> years ago.
<u>VC</u>	Vital capacity - the volume of air from a maximal expiration to a maximum inspiration.
<u>WHO</u>	World Health Organisation
<u>Worker's Daily Exposure</u>	The average work shift concentration of radon progeny for each work area shall be used to calculate each miner's daily exposure. If no monitoring has been conducted in a work area on a particular day, the daily average work shift concentration for that area shall be determined by averaging the results obtained on the last day that monitoring is conducted.
<u>Working Level (WL):</u>	A standard measure of the alpha radiation in air. This energy can come from the radioactive decay of radon (Rn-222) and thoron (Rn-220) gases. The working level is defined as any combination of short-lived radon decay products per liter of air that will result in the emission of 1.3 x 10 <sup>5</sup> million electron volts (MeV) of alpha energy during decay to lead-210.



<u>Working Level Month (WLM):</u>	A working level month (WLM) is the product of the radon progeny concentration in WL and the exposure duration in months. For example, if a miner is exposed at a concentration of 0.083 WL for 1 month (170 hours [hr]),* then the cumulative exposure for the month is 0.083 WLM. If the cumulative exposure of the same miner is 0.083 WLM for each of 12 consecutive months (2,040 hr), then the cumulative exposure for the year is 1 WLM.
-----------------------------------	--





## **SUMMARY**

### **OBJECTIVE**

The objective of this study is to examine the exposure- response relationship between prolonged exposure to low levels of silica, uranium, radon progeny and criteria pollutants and the respiratory health of uranium workers.

### **METHOD**

Initially two pilot studies were done on selected groups of high-risk workers to determine the prevalence of alpha-1-antitrypsin deficiency and the retained burden of uranium in the lungs of exposed workers. The value of sputum cytology was also evaluated. A cross-sectional study was conducted in 1984 to determine the prevalence of spirometric abnormalities among uranium miners. The data from non-smokers without symptoms was used to develop lung function reference values relevant for the present population. Follow up analytical cross-sectional and case control studies were done in 1996 and 1999 to determine the mean independent effect of uranium on the respiratory health of miners and to detect abnormalities in both smokers and non-smokers. Data was collected on employment history, smoking habits, pulmonary function and chest radiographs. To determine the independent mean effect of uranium mining on the respiratory health of workers, only data of non-smokers in exposed cohorts were compared with unexposed control cohorts.

### **RESULTS**

The prevalence of alpha-1-antitrypsin appeared to be high in workers with abnormal spirometric indices. The lung burden of retained uranium in workers in the final product recovery area was within normal limits. The sputum cytology was abandoned because it was found worldwide that cytological screening had no impact on population survival rates. Lung function prediction equations derived from multiple linear regressions were calculated

for the study population which differed from Schoenberg *et al* prediction equations. The data from the analytical cross-sectional study in 1996 suggests that the level of exposure in this study group (without the confounding effect of cigarette smoking) is **not** associated with statistically significant impairment of lung function, increased prevalence of silicosis, tuberculosis and respiratory cancer. Only the FEF<sub>75</sub> was found to be an indicator of early lung abnormality.

Data from the 1999 study supports the hypothesis that there is a small but significant exposure-response relationship between prolonged exposure to low levels of silica dust, and lung function abnormalities (in the absence of radiologically diagnosed silicosis). The prevalence of chronic obstructive pulmonary disease (COPD) and small airways disease (SAD) was small but significantly higher in exposed workers. The risk of developing COPD was 2.7 times higher for exposed workers. The risk for non-smokers was small but significant. The incidence of tuberculosis and lung cancer was not higher than expected (probably because ex-employees were not fully investigated).

## CONCLUSION

Calculation of location specific prediction equations for different ethnic groups is advocated to enable the earliest detection of lung function abnormalities. FEF<sub>75</sub> could be used as an early indicator of lung function impairment (provided strict quality control is maintained). Exposure to a combination of silica dust, radon progeny and smoking was associated with an increased risk of lung function abnormalities, but not with tuberculosis, silicosis and lung cancer. Conclusive assessment must await sufficient latency, and **ex-employees** must be investigated to establish the true magnitude and distribution of the effects of siliceous and uranium dust on the health of workers (which may continue after exposure cease).

## **OPSOMMING**

### **DOELWIT**

Die doelwit van hierdie studie was om die respiratoriese gesondheidstatus van uraanwerkers te bepaal wat langdurig blootgestel was aan lae vlakke van silika, uraanstof, omgewingsbesoedelingstowwe en radon.

### **METODE**

Aanvanklik was twee loodsstudies van stapel gestuur om die voorkoms van alfa-1-antitripsien te bepaal, en om die uraanlading in die longe van werkers vas te stel. Die waarde van sputum-sitologie was ook geëvalueer. 'n Kruissnit-studie was in 1994 geloods om longfunksie abnormaliteite in werkers te identifiseer. Die inligting is gebruik om normale verwysingswaardes vir longfunksies in die studie populasie te bepaal. Opvolg analitiese studies was gedoen in 1996 en 1999 om die onafhanklike effek van uraan sowel as die invloed van lugbesoedeling op die respiratoriese sisteem te bepaal in rokers en nie-rokers. Inligting rakende werk en rooksgeskiedenis, longfunksie en borskas x-strale is ingewin. Om die onafhanklike invloed van lugbesoedeling op die respiratoriese status te bepaal, is slegs inligting van blootgestelde, nie-rokers gebruik en vergelyk met nie blootgestelde, nie-rokers.

### **RESULTATE**

Die voorkomssyfer van alfa-1-antitripsien blyk hoog te wees in werkers met abnormale longfunksies. Die uraanlading in die longe was binne normale perke. Die sputum sitologie projek is laat vaar omdat wêreldwye resultate nie enige impak op die oorlewingsyfers van pasiënte met longkanker gehad het nie. Voorspelde normale waardes vir longfunksies was bereken vir dié studie populasie wat in sommige opsigte verskil het van die van Schoenberg *et al.* Inligting verkry tydens die 1996 kohort studie het geen onafhanklike effek van lugbesoedeling op die longfunksie van nie-rokers aangetoon nie. Die vloeï by 75% van vitale kapasiteit (nie algemeen aanvaarde maatstaf) was egter statisties beduidend abnormaal.

Die inlingting verkry in die 1999 kohort studie, staaf die hipotese dat langdurende, laegraadse blootstelling wél geassosieer word met longfunksie abnormaliteite in beide rokers en nie-rokers (in die afwesigheid van radiologies bewese silikose). Die insidensie van kroniese obstruktiwe lugwega siekte was statisties beduidend verhoog in blootgestelde werkers. Die risiko vir nie-rokers was klein, maar statisties beduidend. Die voorkoms van tuberkulose en longkanker was nie hoër as verwag nie (waarskynlik omdat vorige werknemers nie volledig ondersoek is nie).

### **GEVOLGTREKKING**

Om longfunksie abnormaliteite so vroeg as moontlik op te spoor, moet normale longfunksie verwysingswaardes vir verskillende etniese groepe bepaal word. Die vloeï by 75% van vitale kapasiteit kan gebruik word as 'n indikator van vroeë longfunksie abnormaliteite (indien streng kwaliteitkontrole toegepas word). Blootstelling aan 'n kombinasie van lugbesoedelingstowwe en rook word geassosieer met 'n verhoogde voorkoms van longfunksie abnormaliteite en kroniese obstruktiwe lugweg siekte, maar nie met 'n verhoogde voorkoms van tuberkulose, silikose en longkanker nie. Finale gevolgtrekkings kan slegs gemaak word nadat voldoende voorsiening vir latentheid gemaak is. Vorige werknemers moet ondersoek word om die volledige impak en distribusie van abnormaliteite wat met uraanmynbou geassosieer word, te evalueer, (effekte wat vererger nadat blootstelling gestaak is).